No Class 2 equal: The UK hasn't implemented a blanket ban on compounding distinct peptides similar to the FDA's 2024 conclusion. Having said that, the MHRA can and does choose action from specials brands who develop solutions with no satisfactory medical justification.Quite a few UK potentia